The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of federal price negotiations, which are scheduled to begin this year, with resulting bargained prices going into effect in 2027.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over a decade.

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 receptor agonists.

A comprehensive new study supports evidence of the myriad health benefits of GLP-1 medications like Ozempic and Mounjaro — and even some new potential upsides. Analyzing the medical records of roughly 2.

GLP-1 drugs like Ozempic and Wegovy were initially used — and still are used — to treat diabetes. But in recent years, the uses of this class of drugs have grown in number. Nowadays, Ozempic and its ilk are often used for weight loss — and have shown promise in addressing other health issues.